Lisata Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Lisata Therapeutics disminuyan a un ritmo anual de 5.4%, mientras que sus ingresos anuales crecerán a un ritmo de 127.8% por año. Se espera que el BPA crezca en un 20.8% al año.
Información clave
-5.4%
Tasa de crecimiento de los beneficios
20.81%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.5% |
| Tasa de crecimiento de los ingresos | 127.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 17 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 02
LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk
Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.
Actualización de narrativa • Apr 17
LSTA: Kuva Cash Deal Will Support Future Upside Potential
Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.Actualización de narrativa • Apr 03
LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential
Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.Actualización de narrativa • Mar 20
LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations
Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.Actualización de narrativa • Mar 05
LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside
Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.Actualización de narrativa • Feb 18
LSTA: Pending Kuva Acquisition And Contingent Rights Will Support Future Upside
Analysts have reduced their price target on Lisata Therapeutics from $13.00 to approximately $11.33. They cited updated assumptions around fair value, discount rate, long-term revenue growth, profit margins, and future P/E multiples following recent changes in research coverage.Actualización de narrativa • Feb 04
LSTA: Acquisition Offer And Downgrade Reset Expectations Before Potential Upside
Analysts have trimmed their price target on Lisata Therapeutics from US$15 to US$15.00, reflecting updated assumptions around revenue growth, profit margins, discount rates, and a higher future P/E multiple following recent research, including a downgrade from Brookline. Analyst Commentary Despite the recent trim in the headline price target, bullish analysts still see room for upside if Lisata executes on its plans and delivers against current expectations.Actualización de narrativa • Jan 21
LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade
Analysts have slightly reduced their fair value estimate to US$13.00, citing modest adjustments to the discount rate, long term profit margin expectations, and a lower implied future P/E as they reassess Lisata Therapeutics following a recent downgrade in Street research. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$13.00 fair value as still reflecting upside potential, provided that execution on key clinical and operational milestones tracks internal expectations.Actualización de narrativa • Jan 07
LSTA: Improved Profitability Assumptions Will Support Strong Future Upside Potential
Analysts have modestly lifted their price target for Lisata Therapeutics, citing slightly improved profit margin assumptions at 16.24% and a lower future P/E estimate of 103.37x as key drivers of their updated valuation. Valuation Changes Fair Value: Remains unchanged at 13.0, suggesting the overall valuation anchor has been kept steady.Actualización de narrativa • Dec 24
LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares
Analysts have reduced their price target on Lisata Therapeutics from 32.00 dollars to 15.00 dollars, citing higher discount rates despite stronger projected revenue growth, improved profit margins, and a materially lower future price-to-earnings multiple. What's in the News Lisata Therapeutics and Catalent signed a global product license agreement granting Catalent non exclusive worldwide rights to incorporate certepetide into antibody drug conjugates using its SMARTag technology platform, including the ability to partner with third parties (Key Developments) Under the Catalent collaboration, Lisata is eligible for more than 10 million dollars in tiered study initiation milestone payments plus revenue sharing on future product sales and partnerships (Key Developments) Certepetide, Lisata's proprietary iRGD cyclic peptide, has shown favorable safety, tolerability, and clinical activity in trials aimed at improving the effectiveness of standard of care chemotherapy for pancreatic cancer and other solid tumors (Key Developments) Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., Orphan Drug Designation for glioma and osteosarcoma in the U.S., and Rare Pediatric Disease Designation for osteosarcoma in the U.S. (Key Developments) Preliminary data from the PDAC cohort of the Phase 1/2a CENDIFOX trial of certepetide plus FOLFIRINOX based therapies will be presented at the AACR Special Conference in Cancer Research on Advances in Pancreatic Cancer Research on September 29, 2025, in Boston, Massachusetts (Key Developments) Valuation Changes Fair Value Estimate: Reduced significantly from 32 dollars to 15 dollars per share, reflecting a more conservative assessment despite stronger fundamentals.Actualización de narrativa • Dec 09
LSTA: Upcoming Cancer Trial Milestones Will Drive Strong Upside Potential
Analysts have nudged their price target on Lisata Therapeutics slightly higher to 13.00 dollars from 13.00 dollars, reflecting modest adjustments to the discount rate and long-term valuation assumptions, despite largely unchanged growth and margin expectations. What's in the News Lisata Therapeutics and Catalent entered a global product license agreement granting Catalent worldwide, non exclusive rights to use certepetide in antibody drug conjugates developed on its SMARTag platform, with Lisata eligible for over 10 million dollars in tiered milestone payments plus revenue sharing on future sales and partnerships (Key Developments) Certepetide, Lisata's proprietary internalizing RGD cyclic peptide, will be evaluated by Catalent as a payload across multiple ADCs targeting difficult to treat diseases.Actualización de narrativa • Nov 25
LSTA: Global Licensing Milestones And Trial Results Will Drive Future Upside
Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.Actualización de narrativa • Nov 09
LSTA: Milestone Payments And Clinical Progress Will Drive Future Upside
Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook. What's in the News Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform.Artículo de análisis • Aug 13
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Artículo de análisis • Apr 26
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Nueva narrativa • Apr 14
Certepetide Advancements And Regulatory Approvals Will Set New Care Standards
Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.Artículo de análisis • Dec 24
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Artículo de análisis • Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 14
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders. Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST. CLBS +39.28% premarket to $0.71.Seeking Alpha • Aug 04
Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Caladrius Biosciences press release (NASDAQ:CLBS): Q2 GAAP EPS of -$0.11 beats by $0.01. As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to close in Q3.Artículo de análisis • May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Artículo de análisis • Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 7 | -19 | N/A | N/A | 1 |
| 12/31/2027 | N/A | -21 | N/A | N/A | 1 |
| 12/31/2026 | N/A | -18 | N/A | N/A | 1 |
| 3/31/2026 | 0 | -16 | -14 | -14 | N/A |
| 12/31/2025 | 0 | -17 | -16 | -16 | N/A |
| 9/30/2025 | 1 | -18 | -17 | -17 | N/A |
| 6/30/2025 | 1 | -19 | -16 | -16 | N/A |
| 3/31/2025 | 1 | -19 | -18 | -18 | N/A |
| 12/31/2024 | 1 | -20 | -19 | -19 | N/A |
| 9/30/2024 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -21 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -20 | -19 | -19 | N/A |
| 12/31/2023 | N/A | -21 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -21 | -22 | -22 | N/A |
| 6/30/2023 | N/A | -54 | -23 | -23 | N/A |
| 3/31/2023 | N/A | -56 | -24 | -24 | N/A |
| 12/31/2022 | N/A | -54 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -55 | -20 | -19 | N/A |
| 6/30/2022 | N/A | -25 | -21 | -20 | N/A |
| 3/31/2022 | N/A | -24 | -20 | -20 | N/A |
| 12/31/2021 | N/A | -27 | -22 | -22 | N/A |
| 9/30/2021 | N/A | -26 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -25 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -12 | -13 | -13 | N/A |
| 12/31/2020 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2020 | N/A | -7 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -19 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2019 | N/A | -18 | N/A | -18 | N/A |
| 6/30/2019 | N/A | -17 | N/A | -18 | N/A |
| 3/31/2019 | N/A | -16 | N/A | -19 | N/A |
| 12/31/2018 | N/A | -16 | N/A | -20 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -21 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -22 | N/A |
| 3/31/2018 | N/A | -14 | N/A | -17 | N/A |
| 12/31/2017 | N/A | -16 | N/A | -21 | N/A |
| 9/30/2017 | N/A | -18 | N/A | -20 | N/A |
| 6/30/2017 | N/A | -20 | N/A | -20 | N/A |
| 3/31/2017 | -7 | -26 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -31 | N/A | -24 | N/A |
| 9/30/2016 | 8 | -59 | N/A | -29 | N/A |
| 6/30/2016 | 13 | -64 | N/A | -32 | N/A |
| 3/31/2016 | 27 | -74 | N/A | -33 | N/A |
| 12/31/2015 | 22 | -81 | N/A | -39 | N/A |
| 9/30/2015 | 20 | -59 | N/A | -41 | N/A |
| 6/30/2015 | 18 | -65 | N/A | -46 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que LSTA siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que LSTA siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que LSTA siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que LSTA no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que LSTA no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LSTA se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 23:30 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Lisata Therapeutics, Inc. está cubierta por 11 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jan Wald | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |